{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:39Z","timestamp":1772136399957,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Research Funds from Kangbuk Samsung Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06445-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:31:19Z","timestamp":1751409079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn\u2019s disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Yoon Zi","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Sil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyoung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seon Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-7688","authenticated-orcid":false,"given":"Yon Ho","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4505-4083","authenticated-orcid":false,"given":"Mi Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"6445_CR1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres, J., Mehandru, S. & Colombel, J. F. &Peyrin-Biroulet, L. Crohn\u2019s disease. Lancet 389, 1741\u20131755. https:\/\/doi.org\/10.1016\/S0140-6736(16)31711-1 (2017).","journal-title":"Lancet"},{"key":"6445_CR2","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.3346\/jkms.2018.33.e132","volume":"33","author":"SJ Hong","year":"2018","unstructured":"Hong, S. J. et al. Characteristics and incidence trends for pediatric inflammatory bowel disease in Daegu-Kyungpook Province in korea: a Multi-Center study. J. Korean Med. Sci. 33, e132. https:\/\/doi.org\/10.3346\/jkms.2018.33.e132 (2018).","journal-title":"J. Korean Med. Sci."},{"key":"6445_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","volume":"169","author":"MJ Rosen","year":"2015","unstructured":"Rosen, M. J. & Dhawan, A. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 169, 1053\u20131060. https:\/\/doi.org\/10.1001\/jamapediatrics.2015.1982 (2015).","journal-title":"JAMA Pediatr."},{"key":"6445_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for crohn\u2019s disease. N Engl. J. Med. 362, 1383\u20131395. https:\/\/doi.org\/10.1056\/NEJMoa0904492 (2010).","journal-title":"N Engl. J. Med."},{"key":"6445_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/MPG.0000000000000684","volume":"60","author":"J Kierkus","year":"2015","unstructured":"Kierkus, J. et al. Monotherapy with Infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J. Pediatr. Gastroenterol. Nutr. 60, 580\u2013585. https:\/\/doi.org\/10.1097\/MPG.0000000000000684 (2015).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"6445_CR6","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.cgh.2015.04.010","volume":"13","author":"V Grossi","year":"2015","unstructured":"Grossi, V. et al. Concomitant use of immunomodulators affects the durability of Infliximab therapy in children with crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 13, 1748\u20131756. https:\/\/doi.org\/10.1016\/j.cgh.2015.04.010 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"6445_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPG.0000000000001551","volume":"65","author":"HM Kansen","year":"2017","unstructured":"Kansen, H. M. et al. Less Anti-infliximab antibody formation in paediatric Crohn patients on concomitant immunomodulators. J. Pediatr. Gastroenterol. Nutr. 65, 425\u2013429. https:\/\/doi.org\/10.1097\/MPG.0000000000001551 (2017).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"6445_CR8","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1053\/j.gastro.2008.08.061","volume":"135","author":"G Francis","year":"2008","unstructured":"Francis, G. Withdrawal of immunosuppression in crohn\u2019s disease treated with scheduled Infliximab maintenance. Gastroenterology 135, 2156\u20132157. https:\/\/doi.org\/10.1053\/j.gastro.2008.08.061 (2008).","journal-title":"Gastroenterology"},{"key":"6445_CR9","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","volume":"61","author":"MF Neurath","year":"2012","unstructured":"Neurath, M. F. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61, 1619\u20131635. https:\/\/doi.org\/10.1136\/gutjnl-2012-302830 (2012).","journal-title":"Gut"},{"key":"6445_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","volume":"159","author":"RC Ungaro","year":"2020","unstructured":"Ungaro, R. C. et al. Deep remission at 1 year prevents progression of early crohn\u2019s disease. Gastroenterology 159, 139\u2013147. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.039 (2020).","journal-title":"Gastroenterology"},{"key":"6445_CR11","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner, D. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for Treat-to-Target strategies in IBD. Gastroenterology 160, 1570\u20131583. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031 (2021).","journal-title":"Gastroenterology"},{"key":"6445_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/ecco-jcc\/jjw086","volume":"10","author":"B Kang","year":"2016","unstructured":"Kang, B. et al. Mucosal healing in paediatric patients with Moderate-to-Severe luminal crohn\u2019s disease under combined immunosuppression: escalation versus early treatment. J. Crohns Colitis. 10, 1279\u20131286. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw086 (2016).","journal-title":"J. Crohns Colitis"},{"key":"6445_CR13","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","volume":"12","author":"K van Hoeve","year":"2018","unstructured":"van Hoeve, K. et al. Higher Infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease. J. Crohns Colitis. 12, 1316\u20131325. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy111 (2018).","journal-title":"J. Crohns Colitis"},{"key":"6445_CR14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed crohn\u2019s disease: an open randomised trial. Lancet 371, 660\u2013667. https:\/\/doi.org\/10.1016\/S0140-6736(08)60304-9 (2008).","journal-title":"Lancet"},{"key":"6445_CR15","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/s0016-5085(97)70027-1","volume":"112","author":"G D\u2019Haens","year":"1997","unstructured":"D\u2019Haens, G., Geboes, K., Ponette, E. & Penninckx, F. Healing of severe recurrent ileitis with azathioprine therapy in patients with crohn\u2019s disease. Gastroenterology 112, 1475\u20131481. https:\/\/doi.org\/10.1016\/s0016-5085(97)70027-1 (1997).","journal-title":"Gastroenterology"},{"key":"6445_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.dld.2017.10.017","volume":"50","author":"FP Giugliano","year":"2018","unstructured":"Giugliano, F. P. et al. Does azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study. Dig. Liver Dis. 50, 240\u2013246. https:\/\/doi.org\/10.1016\/j.dld.2017.10.017 (2018).","journal-title":"Dig. Liver Dis."},{"key":"6445_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5223\/pghn.2018.21.1.1","volume":"21","author":"B Kang","year":"2018","unstructured":"Kang, B. Early biologic treatment in pediatric crohn\u2019s disease: catching the therapeutic window of opportunity in early disease by Treat-to-Target. Pediatr. Gastroenterol. Hepatol. Nutr. 21, 1\u201311. https:\/\/doi.org\/10.5223\/pghn.2018.21.1.1 (2018).","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"key":"6445_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","volume":"146","author":"TD Walters","year":"2014","unstructured":"Walters, T. D. et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-\u03b1 vs an Immunomodulator in children with crohn\u2019s disease. Gastroenterology 146, 383\u2013391. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.027 (2014).","journal-title":"Gastroenterology"},{"key":"6445_CR19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/ibd\/izae159","volume":"31","author":"BE Sands","year":"2025","unstructured":"Sands, B. E. et al. Mucosal and transmural healing and Long-term outcomes in crohn\u2019s disease. Inflamm. Bowel Dis. 31, 857\u2013877. https:\/\/doi.org\/10.1093\/ibd\/izae159 (2025).","journal-title":"Inflamm. Bowel Dis."},{"key":"6445_CR20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/apt.17161","volume":"56","author":"SY Choi","year":"2022","unstructured":"Choi, S. Y. et al. Transmural healing evaluated by magnetic resonance enterography in paediatric patients with crohn\u2019s disease receiving maintenance treatment with biologics. Aliment. Pharmacol. Ther. 56, 1146\u20131156. https:\/\/doi.org\/10.1111\/apt.17161 (2022).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"6445_CR21","doi-asserted-by":"publisher","unstructured":"Brandse, J. F. et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 14, 251\u2013258 e251-252  https:\/\/doi.org\/10.1016\/j.cgh.2015.10.029 (2016).","DOI":"10.1016\/j.cgh.2015.10.029"},{"key":"6445_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/MIB.0000000000000284","volume":"21","author":"NL Zitomersky","year":"2015","unstructured":"Zitomersky, N. L. et al. Antibodies to Infliximab are associated with lower Infliximab levels and increased likelihood of surgery in pediatric IBD. Inflamm. Bowel Dis. 21, 307\u2013314. https:\/\/doi.org\/10.1097\/MIB.0000000000000284 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"6445_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/ecco-jcc\/jjx149","volume":"12","author":"DV Mogensen","year":"2018","unstructured":"Mogensen, D. V. et al. A role for thiopurine metabolites in the synergism between thiopurines and Infliximab in inflammatory bowel disease. J. Crohns Colitis. 12, 298\u2013305. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx149 (2018).","journal-title":"J. Crohns Colitis"},{"key":"6445_CR24","doi-asserted-by":"publisher","unstructured":"Yarur, A. J. et al. Combination therapy with immunomodulators improves the pharmacokinetics of infliximab but not vedolizumab or ustekinumab. Clin. Gastroenterol. Hepatol. 21, 2908\u20132917 e2910  https:\/\/doi.org\/10.1016\/j.cgh.2022.10.016 (2023).","DOI":"10.1016\/j.cgh.2022.10.016"},{"key":"6445_CR25","doi-asserted-by":"publisher","unstructured":"Papamichael, K. et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 17, 1655\u20131668 e1653 https:\/\/doi.org\/10.1016\/j.cgh.2019.03.037 (2019).","DOI":"10.1016\/j.cgh.2019.03.037"},{"key":"6445_CR26","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.dld.2019.05.001","volume":"51","author":"V Polakovicova","year":"2019","unstructured":"Polakovicova, V. et al. Positive Pharmacokinetic effect of azathioprine co-medication on Infliximab trough levels is dose-dependent. Dig. Liver Dis. 51, 1112\u20131116. https:\/\/doi.org\/10.1016\/j.dld.2019.05.001 (2019).","journal-title":"Dig. Liver Dis."},{"key":"6445_CR27","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/ibd\/izad307","volume":"30","author":"RJ Colman","year":"2024","unstructured":"Colman, R. J. et al. Infliximab monotherapy vs combination therapy for pediatric crohn\u2019s disease exhibit similar pharmacokinetics. Inflamm. Bowel Dis. 30, 1678\u20131685. https:\/\/doi.org\/10.1093\/ibd\/izad307 (2024).","journal-title":"Inflamm. Bowel Dis."},{"key":"6445_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ibd\/izy203","volume":"25","author":"S Lega","year":"2019","unstructured":"Lega, S. et al. Proactively optimized Infliximab monotherapy is as effective as combination therapy in IBD. Inflamm. Bowel Dis. 25, 134\u2013141. https:\/\/doi.org\/10.1093\/ibd\/izy203 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"6445_CR29","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.15179","volume":"49","author":"D Drobne","year":"2019","unstructured":"Drobne, D. et al. Optimised Infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment. Pharmacol. Ther. 49, 880\u2013889. https:\/\/doi.org\/10.1111\/apt.15179 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"6445_CR30","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/ibd\/izad277","volume":"30","author":"H Hoelz","year":"2024","unstructured":"Hoelz, H. et al. Pediatric IBD patients treated with Infliximab and proactive drug monitoring benefit from early concomitant Immunomodulatory therapy: A retrospective analysis of a 10-Year Real-Life cohort. Inflamm. Bowel Dis. 30, 2004\u20132018. https:\/\/doi.org\/10.1093\/ibd\/izad277 (2024).","journal-title":"Inflamm. Bowel Dis."},{"key":"6445_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5005\/jp-journals-10071-23738","volume":"25","author":"P Debnath","year":"2021","unstructured":"Debnath, P. et al. Thiopurine-induced myelosuppression with severe Sepsis in a patient with crohn\u2019s disease: A case report. Indian J. Crit. Care Med. 25, 228\u2013230. https:\/\/doi.org\/10.5005\/jp-journals-10071-23738 (2021).","journal-title":"Indian J. Crit. Care Med."},{"key":"6445_CR32","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/gut.34.8.1081","volume":"34","author":"WR Connell","year":"1993","unstructured":"Connell, W. R., Kamm, M. A., Ritchie, J. K. & Lennard-Jones, J. E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34, 1081\u20131085. https:\/\/doi.org\/10.1136\/gut.34.8.1081 (1993).","journal-title":"Gut"},{"key":"6445_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","volume":"58","author":"A Levine","year":"2014","unstructured":"Levine, A. et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 58, 795\u2013806. https:\/\/doi.org\/10.1097\/MPG.0000000000000239 (2014).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"6445_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno, M. et al. Development and validation of a new, simplified endoscopic activity score for crohn\u2019s disease: the SES-CD. Gastrointest. Endosc. 60, 505\u2013512. https:\/\/doi.org\/10.1016\/s0016-5107(04)01878-4 (2004).","journal-title":"Gastrointest. Endosc"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06445-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06445-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06445-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:31:19Z","timestamp":1751409079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06445-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6445"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06445-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4512921\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"1 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23025"}}